{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:58Z","timestamp":1790821558605,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04514-9","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:39:19Z","timestamp":1766147959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Hind","family":"Alnajashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain Ali J","family":"Almohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Salah","family":"Morad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra Wadi","family":"Bin Saddiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar Faisal","family":"Kushara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan Mohammed Khair","family":"Al Zoabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wejdan Ahmed","family":"Aldawsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah Ibrahim","family":"Almuhaysin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayar Ahmed","family":"Gasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hams Akram","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer Nidal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"8","key":"4514_CR1","doi-asserted-by":"publisher","first-page":"e37297","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-hussaniy HA. Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine. 2024;103(8):e37297. https:\/\/doi.org\/10.1097\/MD.0000000000037297.","journal-title":"Medicine"},{"key":"4514_CR2","doi-asserted-by":"publisher","first-page":"175628642110076","DOI":"10.1177\/17562864211007687","volume":"14","author":"S Haase","year":"2021","unstructured":"Haase S, Linker RA. Inflammation in multiple sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211007688. https:\/\/doi.org\/10.1177\/17562864211007687.","journal-title":"Ther Adv Neurol Disord"},{"key":"4514_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26:1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler"},{"issue":"22","key":"4514_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/jama.2022.14236","volume":"328","author":"R Marcus","year":"2022","unstructured":"Marcus R. What is multiple sclerosis? JAMA. 2022;328(22):2078. https:\/\/doi.org\/10.1001\/jama.2022.14236.","journal-title":"JAMA"},{"issue":"5","key":"4514_CR5","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(5):e1029\u201340. https:\/\/doi.org\/10.1212\/WNL.0000000000007035.","journal-title":"Neurology"},{"issue":"7","key":"4514_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/01.NPR.0000000000000202","volume":"49","author":"J Hernandez","year":"2024","unstructured":"Hernandez J. Multiple sclerosis treatment review for primary care providers. Nurse Pract. 2024;49(7):38\u201347. https:\/\/doi.org\/10.1097\/01.NPR.0000000000000202.","journal-title":"Nurse Pract"},{"issue":"1","key":"4514_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27\u201340. https:\/\/doi.org\/10.1111\/ene.13819.","journal-title":"Eur J Neurol"},{"issue":"15","key":"4514_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(15):278\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000000560.","journal-title":"Neurology"},{"key":"4514_CR9","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133:1380-1390.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049.","journal-title":"Am J Med"},{"issue":"1","key":"4514_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78\u201388. https:\/\/doi.org\/10.1016\/S1474-4422(22)00289-7.","journal-title":"Lancet Neurol"},{"key":"4514_CR11","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","volume":"11","author":"J van Langelaar","year":"2020","unstructured":"van Langelaar J, Rijvers L, Smolders J, van Luijn MM. B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol. 2020;11:760. https:\/\/doi.org\/10.3389\/fimmu.2020.00760.","journal-title":"Front Immunol"},{"key":"4514_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3389\/fimmu.2020.00374","volume":"11","author":"BL Guerrero","year":"2020","unstructured":"Guerrero BL, Sicotte NL. Microglia in multiple sclerosis: friend or foe? Front Immunol. 2020;11:374. https:\/\/doi.org\/10.3389\/fimmu.2020.00374.","journal-title":"Front Immunol"},{"issue":"325","key":"4514_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"23","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;23(325):765\u201379. https:\/\/doi.org\/10.1001\/jama.2020.26858.Erratum in: JAMA. 2021;325:2211. https:\/\/doi.org\/10.1001\/jama.2021.7928. PMID: 33620411.","journal-title":"JAMA"},{"key":"4514_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg S\u00f8rensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389:1347\u201356.","journal-title":"Lancet"},{"key":"4514_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/nmt-2021-0058.PMID:36314777;PMCID:PMC10072078","volume":"13","author":"M Amin","year":"2023","unstructured":"Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023;13:47\u201370. https:\/\/doi.org\/10.2217\/nmt-2021-0058.PMID:36314777;PMCID:PMC10072078.","journal-title":"Neurodegener Dis Manag"},{"key":"4514_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/jpm12010119","volume":"12","author":"B Casanova","year":"2022","unstructured":"Casanova B, Quintanilla-Bord\u00e1s C, Gasc\u00f3n F. Escalation vs. early intense therapy in multiple sclerosis. J Pers Med. 2022;12:119. https:\/\/doi.org\/10.3390\/jpm12010119.","journal-title":"J Pers Med"},{"key":"4514_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40120-022-00430-z","volume":"12","author":"J De S\u00e8ze","year":"2023","unstructured":"De S\u00e8ze J, Suchet L, Mekies C, Manchon E, Labauge P, Guennoc AM, et al. The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an expert consensus. Neurol Ther. 2023;12:351\u201369. https:\/\/doi.org\/10.1007\/s40120-022-00430-z.","journal-title":"Neurol Ther"},{"key":"4514_CR18","first-page":"93","volume":"7","author":"K Janiec","year":"2001","unstructured":"Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit. 2001;7:93\u20138.","journal-title":"Med Sci Monit"},{"key":"4514_CR19","first-page":"225","volume":"60","author":"A Niezgoda","year":"2001","unstructured":"Niezgoda A, Losy J, Mehta PD. Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia Morphol (Warsz). 2001;60:225\u20138.","journal-title":"Folia Morphol (Warsz)"},{"key":"4514_CR20","unstructured":"Drugs and lactation database (LactMed\u00ae). Bethesda, MD: National Institute of Child Health and Human Development; 2006\u2013. Cladribine. 2023 Sep 15. PMID: 29999874."},{"key":"4514_CR21","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/brain\/awy151","volume":"141","author":"J Machado-Santos","year":"2018","unstructured":"Machado-Santos J, Saji E, Tr\u00f6scher AR, Paunovic M, Liblau R, Gabriely G, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141:2066\u201382. https:\/\/doi.org\/10.1093\/brain\/awy151.","journal-title":"Brain"},{"key":"4514_CR22","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s40120-024-00650-5","volume":"13","author":"B Yamout","year":"2024","unstructured":"Yamout B, Alroughani R, Inshasi J, Farouk S, Abdulla F, Al-Jarki NY, et al. Practical recommendations from the Gulf region on the therapeutic use of cladribine tablets for the management of relapsing multiple sclerosis: impact of the latest real-world evidence on clinical practice. Neurol Ther. 2024;13:1321\u201335. https:\/\/doi.org\/10.1007\/s40120-024-00650-5.","journal-title":"Neurol Ther"},{"key":"4514_CR23","unstructured":"Summary of Product Characteristics for Mavenclad (cladribine tablets). https:\/\/www.medic.ines.org.uk\/emc\/product\/8435\/smpc."},{"key":"4514_CR24","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24:1594\u2013604. https:\/\/doi.org\/10.1177\/1352458517727603. (PMID: 28870107).","journal-title":"Mult Scler"},{"key":"4514_CR25","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"key":"4514_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:1\u201310.","journal-title":"Syst Rev"},{"key":"4514_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","author":"J Higgins","year":"2011","unstructured":"Higgins J, The Cochrane Collaboration. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"4514_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CKL Lo","year":"2014","unstructured":"Lo CKL, Mertz D, Loeb M. Newcastle-ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45. https:\/\/doi.org\/10.1186\/1471-2288-14-45.","journal-title":"BMC Med Res Methodol"},{"key":"4514_CR29","unstructured":"Review Manager, 5 (RevMan 5) [Computer program]. Version 5.4. Copenhagen: The Cochrane Collaboration; 2020."},{"key":"4514_CR30","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane Handbook for Systematic Reviews of interventions, Version 6.2. https:\/\/training.cochrane.org\/handbook."},{"key":"4514_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1352458510391344","volume":"17","author":"S Cook","year":"2011","unstructured":"Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine tablets treating multiple sclerosis orallY) study. Mult Scler J. 2011;17:578\u201393.","journal-title":"Mult Scler J"},{"key":"4514_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, Comi G, Cree BAC, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (Oracle MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257\u201367.","journal-title":"Lancet Neurol"},{"key":"4514_CR33","doi-asserted-by":"publisher","first-page":"104791","DOI":"10.1016\/j.msard.2023.104791","volume":"76","author":"WJ Brownlee","year":"2023","unstructured":"Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, et al. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: a real-world study. Mult Scler Relat Disord. 2023;76:104791.","journal-title":"Mult Scler Relat Disord"},{"key":"4514_CR34","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/13524585231161494","volume":"29","author":"G Giovannoni","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, et al. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of Classic-MS: an ambispective study. Mult Scler J. 2023;29:719\u201330.","journal-title":"Mult Scler J"},{"key":"4514_CR35","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00415-023-11700-7","volume":"270","author":"C Zanetta","year":"2023","unstructured":"Zanetta C, Rocca MA, Meani A, Martinelli V, Ferr\u00e8 L, Moiola L, et al. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing\u2013remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. 2023;270:3553\u201364.","journal-title":"J Neurol"},{"key":"4514_CR36","doi-asserted-by":"publisher","first-page":"e16250","DOI":"10.1111\/ene.16250","volume":"31","author":"I Schiavetti","year":"2024","unstructured":"Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, et al. Therapeutic choices and disease activity after 2 years of treatment with cladribine: an Italian multicenter study (CladStop). Eur J Neurol. 2024;31:e16250.","journal-title":"Eur J Neurol"},{"key":"4514_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11593310-000000000-00000","volume":"32","author":"S Ali","year":"2012","unstructured":"Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, et al. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY study. Clin Drug Investig. 2012;32:15\u201327.","journal-title":"Clin Drug Investig"},{"key":"4514_CR38","doi-asserted-by":"crossref","unstructured":"Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, et al. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Mult Scler J. 2024;30(9):1163\u20131175.","DOI":"10.1177\/13524585241267211"},{"key":"4514_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1352458520921087","volume":"27","author":"N Lizak","year":"2021","unstructured":"Lizak N, Hodgkinson S, Butler E, Lechner-Scott J, Slee M, McCombe PA, et al. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy. Mult Scler J. 2021;27:465\u201374.","journal-title":"Mult Scler J"},{"key":"4514_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1352458517690269","volume":"24","author":"N De Stefano","year":"2018","unstructured":"De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler J. 2018;24:222\u20136.","journal-title":"Mult Scler J"},{"key":"4514_CR41","doi-asserted-by":"publisher","first-page":"175628641988759","DOI":"10.1177\/1756286419887596","volume":"12","author":"N M\u00f6hn","year":"2019","unstructured":"M\u00f6hn N, Skripuletz T, S\u00fchs KW, Menck S, Vo\u00df E, Stangel M. Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. Ther Adv Neurol Disord. 2019;12:1756286419887596.","journal-title":"Ther Adv Neurol Disord"},{"key":"4514_CR42","doi-asserted-by":"publisher","first-page":"175628642092268","DOI":"10.1177\/1756286420922685","volume":"13","author":"F Patti","year":"2020","unstructured":"Patti F, Visconti A, Capacchione A, Roy S, Trojano M, Clarinet-Ms Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020;13:1756286420922685.","journal-title":"Ther Adv Neurol Disord"},{"key":"4514_CR43","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1177\/1352458517728812","volume":"24","author":"T Kalincik","year":"2018","unstructured":"Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, et al. Cladribine versus fingolimod, natalizumab and interferon \u03b2 for multiple sclerosis. Mult Scler J. 2018;24:1617\u201326.","journal-title":"Mult Scler J"},{"key":"4514_CR44","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.msard.2023.104951","volume":"79","author":"W Brownlee","year":"2023","unstructured":"Brownlee W, Amin A, Ashton L, Herbert A. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study. Mult Scler Relat Disord. 2023;79:104951.","journal-title":"Mult Scler Relat Disord"},{"key":"4514_CR45","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1212\/NXI.0000000000000878","volume":"7","author":"A Signori","year":"2020","unstructured":"Signori A, Sacc\u00e0 F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, et al. Cladribine vs other drugs in MS: merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7:e878.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4514_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, et al. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler J. 2023;29:221\u201335.","journal-title":"Mult Scler J"},{"key":"4514_CR47","first-page":"1330","volume":"93","author":"C Zhu","year":"2022","unstructured":"Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, et al. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022;93:1330\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4514_CR48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, S\u00f8rensen PS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326.","journal-title":"N Engl J Med"},{"key":"4514_CR49","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1007\/s10072-023-06794-w","volume":"44","author":"F Nabizadeh","year":"2023","unstructured":"Nabizadeh F, Mohamadi M, Rahmani S, Rajabi R, Afrashteh F, Najdaghi S, et al. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023;44:3045\u201357.","journal-title":"Neurol Sci"},{"key":"4514_CR50","doi-asserted-by":"publisher","first-page":"107885","DOI":"10.1016\/j.clineuro.2023.107885","volume":"232","author":"J Al-Hashel","year":"2023","unstructured":"Al-Hashel J, Ahmed SF, AlMojel M, Alroughani R. A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on cladribine. Clin Neurol Neurosurg. 2023;232:107885.","journal-title":"Clin Neurol Neurosurg"},{"key":"4514_CR51","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","volume":"34","author":"MK Siddiqui","year":"2018","unstructured":"Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing\u2013remitting multiple sclerosis. Curr Med Res Opin. 2018;34:1361\u201371.","journal-title":"Curr Med Res Opin"},{"key":"4514_CR52","doi-asserted-by":"publisher","first-page":"175628561775336","DOI":"10.1177\/1756285617753365","volume":"11","author":"G Comi","year":"2018","unstructured":"Comi G, Cook S, Rammohan K, Soelberg Sorensen P, Vermersch P, Adeniji AK, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing\u2013remitting multiple sclerosis: the CLARITY extension study. Ther Adv Neurol Disord. 2018;11:1756285617753365.","journal-title":"Ther Adv Neurol Disord"},{"key":"4514_CR53","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ana.410330511","volume":"33","author":"ME Smith","year":"1993","unstructured":"Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of Gadopentetate dimeglumine\u2013enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480\u20139.","journal-title":"Ann Neurol"},{"key":"4514_CR54","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/ana.21606","volume":"65","author":"MP Sormani","year":"2009","unstructured":"Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009;65:268\u201375.","journal-title":"Ann Neurol"},{"key":"4514_CR55","unstructured":"DailyMed. Mavenclad \u2013 cladribine tablet [Internet]. Bethesda, MD: United States National Library of Medicine; updated 2024 May 21. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9c75e30a-a410-40f1-b653-04d532bd9144. Accessed 2025 May 22."},{"key":"4514_CR56","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4514_CR57","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/03007995.2023.2256220","volume":"39","author":"H Butzkueven","year":"2023","unstructured":"Butzkueven H, Hillert J, Soilu-H\u00e4nninen M, Ziemssen T, Kuhle J, Wergeland S, et al. The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis. Curr Med Res Opin. 2023;39:1367\u201374.","journal-title":"Curr Med Res Opin"},{"key":"4514_CR58","doi-asserted-by":"publisher","first-page":"578164","DOI":"10.1016\/j.jneuroim.2023.578164","volume":"382","author":"I Adamec","year":"2023","unstructured":"Adamec I, Brecl Jakob G, Rajda C, Drulovi\u0107 J, Radulovi\u0107 L, Ba\u0161i\u0107 Kes V, et al. Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers. J Neuroimmunol. 2023;382:578164.","journal-title":"J Neuroimmunol"},{"key":"4514_CR59","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","volume":"29","author":"S Cook","year":"2019","unstructured":"Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157\u201367.","journal-title":"Mult Scler Relat Disord"},{"key":"4514_CR60","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.3389\/fimmu.2018.02669","volume":"9","author":"M Kaufmann","year":"2018","unstructured":"Kaufmann M, Haase R, Proschmann U, Ziemssen T, Akg\u00fcn K. Real world lab data: patterns of lymphocyte counts in fingolimod treated patients. Front Immunol. 2018;9:2669.","journal-title":"Front Immunol"},{"key":"4514_CR61","doi-asserted-by":"publisher","first-page":"e0228380","DOI":"10.1371\/journal.pone.0228380","volume":"15","author":"M Hjorth","year":"2020","unstructured":"Hjorth M, Dandu N, Mellerg\u00e5rd J. Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets. PLoS ONE. 2020;15:e0228380.","journal-title":"PLoS ONE"},{"key":"4514_CR62","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","volume":"89","author":"BM Jacobs","year":"2018","unstructured":"Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:1266\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4514_CR63","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3390\/cells10123488","volume":"10","author":"N Fissolo","year":"2021","unstructured":"Fissolo N, Calvo-Barreiro L, Eixarch H, Boschert U, Espejo C, Montalban X, et al. Immunomodulatory effects associated with cladribine treatment. Cells. 2021;10:3488.","journal-title":"Cells"},{"key":"4514_CR64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34:28\u201335.","journal-title":"Clin Neuropharmacol"},{"key":"4514_CR65","doi-asserted-by":"publisher","first-page":"175628641985498","DOI":"10.1177\/1756286419854986","volume":"12","author":"O Stuve","year":"2019","unstructured":"Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986.","journal-title":"Ther Adv Neurol Disord"},{"key":"4514_CR66","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, Rieckmann P, S\u00f8rensen PS, Vermersch P, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord"},{"key":"4514_CR67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/ene.15579","volume":"30","author":"R Cortese","year":"2023","unstructured":"Cortese R, Battaglini M, Sormani MP, Luchetti L, Gentile G, Inderyas M, et al. Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets. Eur J Neurol. 2023;30:179\u201386.","journal-title":"Eur J Neurol"},{"issue":"31","key":"4514_CR68","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/13524585251313749","volume":"135245852513137","author":"A Achiron","year":"2025","unstructured":"Achiron A, Warszawer Y, Nissan Y, Kerpel A, Hoffmann C, Harari G, et al. Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study. Mult Scler J. 2025;13524585251313748(31):689\u201395.","journal-title":"Mult Scler J"},{"key":"4514_CR69","doi-asserted-by":"publisher","first-page":"e0149685","DOI":"10.1371\/journal.pone.0149685","volume":"11","author":"P Branger","year":"2016","unstructured":"Branger P, Parienti JJ, Sormani MP, Defer G. The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis. PLoS ONE. 2016;11:e0149685.","journal-title":"PLoS ONE"},{"key":"4514_CR70","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5603\/PJNNS.a2022.0068","volume":"56","author":"K Piasecka-Stryczy\u0144ska","year":"2022","unstructured":"Piasecka-Stryczy\u0144ska K, Kaczy\u0144ski \u0141, Rolka M, Homa M, Sta\u015bkiewicz W, Paczwa P, et al. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. Neurol Neurochir Pol. 2022;56:480\u20139.","journal-title":"Neurol Neurochir Pol"},{"key":"4514_CR71","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2174\/1570159X21666230322140711","volume":"22","author":"S Arena","year":"2024","unstructured":"Arena S, Chisari CG, Toscano S, Bucello S, Grimaldi LM, Ragonese P, et al. Real-world effectiveness of cladribine for patients with multiple sclerosis: a Sicilian multicentric experience (REWIND study). Curr Neuropharmacol. 2024;22:1271\u201383.","journal-title":"Curr Neuropharmacol"},{"key":"4514_CR72","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","volume":"38","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, et al. Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies. Adv Ther. 2021;38:4975\u201385.","journal-title":"Adv Ther"},{"issue":"4","key":"4514_CR73","doi-asserted-by":"publisher","first-page":"e200415","DOI":"10.1212\/NXI.0000000000200415","volume":"12","author":"T Guerra","year":"2025","unstructured":"Guerra T, Copetti M, Zanetta C, Patti F, Chisari CG, Barbuti E, et al. The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200415. https:\/\/doi.org\/10.1212\/NXI.0000000000200415.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04514-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04514-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04514-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:02:37Z","timestamp":1766152957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04514-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4514"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04514-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hind Alnajashi received speaker honoraria from Biogen, Merck, Novartis, and Roche outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"510"}}